ANI Pharmaceuticals (NASDAQ:ANIP) Raised to “Hold” at ValuEngine

ValuEngine upgraded shares of ANI Pharmaceuticals (NASDAQ:ANIP) from a sell rating to a hold rating in a report issued on Monday, February 4th.

A number of other research firms have also recently weighed in on ANIP. BidaskClub cut shares of ANI Pharmaceuticals from a buy rating to a hold rating in a research report on Friday, December 7th. Cantor Fitzgerald set a $74.00 target price on shares of ANI Pharmaceuticals and gave the company a buy rating in a research report on Tuesday, November 6th. Finally, Canaccord Genuity set a $70.00 price objective on shares of ANI Pharmaceuticals and gave the stock a buy rating in a research report on Friday, November 9th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. ANI Pharmaceuticals presently has a consensus rating of Buy and a consensus target price of $71.50.

Shares of ANIP stock traded down $1.48 during trading hours on Monday, hitting $64.31. The company’s stock had a trading volume of 89,386 shares, compared to its average volume of 57,350. The company has a market capitalization of $715.63 million, a P/E ratio of 13.95 and a beta of 2.51. The company has a debt-to-equity ratio of 1.04, a current ratio of 3.34 and a quick ratio of 2.49. ANI Pharmaceuticals has a 12-month low of $36.92 and a 12-month high of $72.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Wednesday, February 27th. The specialty pharmaceutical company reported $1.32 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.24 by $0.08. The firm had revenue of $57.12 million for the quarter, compared to the consensus estimate of $53.48 million. ANI Pharmaceuticals had a net margin of 0.23% and a return on equity of 28.39%. The firm’s quarterly revenue was up 20.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.08 earnings per share. As a group, sell-side analysts forecast that ANI Pharmaceuticals will post 5.66 earnings per share for the current year.

Hedge funds have recently made changes to their positions in the business. Public Employees Retirement System of Ohio purchased a new position in shares of ANI Pharmaceuticals in the second quarter valued at approximately $603,000. Northern Trust Corp lifted its stake in ANI Pharmaceuticals by 4.2% in the second quarter. Northern Trust Corp now owns 116,806 shares of the specialty pharmaceutical company’s stock worth $7,803,000 after acquiring an additional 4,710 shares during the last quarter. First Manhattan Co. lifted its stake in ANI Pharmaceuticals by 48.0% in the third quarter. First Manhattan Co. now owns 215,695 shares of the specialty pharmaceutical company’s stock worth $12,195,000 after acquiring an additional 70,000 shares during the last quarter. Strs Ohio lifted its stake in ANI Pharmaceuticals by 10.7% in the third quarter. Strs Ohio now owns 13,500 shares of the specialty pharmaceutical company’s stock worth $763,000 after acquiring an additional 1,300 shares during the last quarter. Finally, Perkins Capital Management Inc. raised its holdings in ANI Pharmaceuticals by 6.3% during the third quarter. Perkins Capital Management Inc. now owns 32,950 shares of the specialty pharmaceutical company’s stock worth $1,863,000 after purchasing an additional 1,950 shares in the last quarter. 62.46% of the stock is owned by institutional investors.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and hydrocortisone enema and cortenema to treat ulcerative colitis.

Recommended Story: Marijuana Stocks Future Looks Bright

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.